SCHEMBL5338951

SCHEMBL5338951

Cc1cnc(N)c2nc(C)n(CCCCSc3ncccn3)c12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.36
RAB9A P51151 5/20 0.36
SMN1; SMN2 Q16637 4/20 0.36
KMT2A Q03164 4/20 0.36
MEN1 O00255 3/20 0.36
KDM1A O60341 2/20 0.35
ALDH1A1 P00352 3/20 0.34
L3MBTL1 Q9Y468 2/20 0.33
GAA P10253 2/20 0.33
NFKB1 P19838 1/20 0.33
NFKB2 Q00653 1/20 0.33
RELA Q04206 1/20 0.33
HSD17B10 Q99714 3/20 0.33
MAPK1 P28482 2/20 0.33
TSHR P16473 2/20 0.33
ALOX15 P16050 1/20 0.33
MAPT P10636 3/20 0.33
PIM1 P11309 1/20 0.33
CSNK2A2 P19784 1/20 0.33
CSNK2B P67870 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4872210 0.99 NPC1 (0.35) NPC1RAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL4792132 0.96 KDM1A (0.38) NPC1RAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL4827783 0.88 TLR7 (0.38) NPC1RAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL4882071 0.87 TLR7 (0.37) NPC1RAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL4873497 0.86 TLR7 (0.39) NPC1RAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL4794348 0.85 TLR7 (0.38) SMN1; SMN2ALDH1A1GAAHSD17B10ALOX15
SCHEMBL4875538 0.85 TLR7 (0.45) SMN1; SMN2TLR7
SCHEMBL4791330 0.85 TLR7 (0.39) NPC1RAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL4792503 0.84 TLR7 (0.36) NPC1RAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL4790565 0.84 CSNK2A1 (0.36) TSHRPIM1CSNK2A2CSNK2BCSNK2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220758-B2 Ether substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2007-05-22 US disclosed
US-20060252792-A1 ETHER SUBSTITUTED IMIDAZOPYRIDINES 3M INNOVATIVE PROPERTIES COMPANY 2006-11-09 US disclosed
US-7125890-B2 Ether substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-10-24 US disclosed
US-20050032830-A1 Immunology for viral diseases and biosynthesis of cytokines of anticancer drugs for tumors 3M INNOVATIVE PROPERTIES COMPANY 2005-02-10 US disclosed
US-6797718-B2 Ether substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2004-09-28 US disclosed
US-20040010007-A1 Ether substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2004-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252792-A1 ETHER SUBSTITUTED IMIDAZOPYRIDINES IL2, IL4, MYD88 NPC1 3237/4885RAB9A 3015/4885SMN1; SMN2 2887/4885
US-20050032830-A1 Immunology for viral diseases and biosynthesis of cytokines of anticancer drugs for tumors IL2, IFNG, TSLP NPC1 3418/4885RAB9A 2659/4885SMN1; SMN2 4130/4885
US-20040010007-A1 Ether substituted imidazopyridines IL2, IL4, MYD88 NPC1 3237/4885RAB9A 3015/4885SMN1; SMN2 2887/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.